---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-038061"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:00:53.956452+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track

## Summary
- Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
- Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.
- Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.
- VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.
- Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated.

## SEC filing metadata
- accession: 0001213900-26-038061
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/ea0279571-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-038061
- JSON: https://secwatch.observer/filing/0001213900-26-038061.json
- Plain text: https://secwatch.observer/filing/0001213900-26-038061.txt

## Key facts
- Earnings Releases
  Allarity Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.
  - Period: the fiscal year ended December 31, 2025
  - Result: reported results
  source text: On March 31, 2026, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.